A 5-year follow-up to evaluate the efficacy and safety of ofatumumab added to fludarabine and cyclophosphamide in patients with relapsed chronic lymphocytic leukemia: final analysis of the COMPLEMENT 2 trial

Click to increase image sizeClick to decrease image size

Acknowledgements

We thank the patients and their families, investigators, and staff from all the participating sites. We thank Satrupa Das, PhD, and Amrita Dutta, PhD, of Novartis Healthcare Pvt. Ltd. for providing medical editorial assistance with this manuscript.

Ethical approval

The study was conducted in accordance with the Good Clinical Practice guidelines and the guiding principles of the Declaration of Helsinki. The institutional review board or ethics committee of each participating center reviewed the protocol.

Informed consent disclosure

All patients were required to provide written informed consent prior to enrolling in the study.

Disclosure statement

Disclosure forms provided by the authors are available online.

Data availability

All data generated or analyzed during this study are included in this published article.

Additional information

Funding

This work was supported by research funding from Novartis Pharma AG, Basel, Switzerland.